These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28532488)

  • 1. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
    Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
    Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City.
    Behrends CN; Paone D; Nolan ML; Tuazon E; Murphy SM; Kapadia SN; Jeng PJ; Bayoumi AM; Kunins HV; Schackman BR
    J Subst Abuse Treat; 2019 Nov; 106():79-88. PubMed ID: 31540615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.
    Jozaghi E; Reid AA; Andresen MA; Juneau A
    Subst Abuse Treat Prev Policy; 2014 Aug; 9():31. PubMed ID: 25091704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States.
    Semaan S; Fleming P; Worrell C; Stolp H; Baack B; Miller M
    Drug Alcohol Depend; 2011 Nov; 118(2-3):100-10. PubMed ID: 21515001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding supervised injection facilities across Canada: lessons from the Vancouver experience.
    Young S; Fairbairn N
    Can J Public Health; 2018 Apr; 109(2):227-230. PubMed ID: 29981039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 13. Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs.
    Jozaghi E; Jackson A
    Int J Health Policy Manag; 2015 Mar; 4(6):373-9. PubMed ID: 26029896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of Vancouver's supervised injection facility.
    Bayoumi AM; Zaric GS
    CMAJ; 2008 Nov; 179(11):1143-51. PubMed ID: 19015565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.
    Salmon AM; van Beek I; Amin J; Kaldor J; Maher L
    Addiction; 2010 Apr; 105(4):676-83. PubMed ID: 20148794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study.
    Kennedy MC; Hayashi K; Milloy MJ; Wood E; Kerr T
    PLoS Med; 2019 Nov; 16(11):e1002964. PubMed ID: 31770391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia.
    Roxburgh A; Livingston M; Dietze P; Nielsen S; Cogger S; Bartlett M; Day C; Latimer J; Jauncey M; Clark N
    Public Health; 2023 Nov; 224():90-97. PubMed ID: 37742585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration.
    Wolfson-Stofko B; Elliott L; Bennett AS; Curtis R; Gwadz M
    Int J Drug Policy; 2018 Dec; 62():67-73. PubMed ID: 30359875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada.
    Karamouzian M; Dohoo C; Forsting S; McNeil R; Kerr T; Lysyshyn M
    Harm Reduct J; 2018 Sep; 15(1):46. PubMed ID: 30200991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.